SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Rhea-AI Summary

SCYNEXIS, Inc. (NASDAQ: SCYX) announced upcoming presentations of preclinical efficacy and pharmacokinetic data on its second-generation fungerp candidate SCY-247 at IDWeek 2024 in Los Angeles, CA from October 16-19, 2024. The company will present two sessions:

1. An oral presentation titled 'Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections' on October 17.

2. A poster presentation titled 'SCY-247: A Second-generation IV/Oral Triterpenoid Antifungal with Extensive Tissue Distribution and Pharmacokinetics, and Low Drug-Drug Interaction Potential' on October 18.

Both presentations will be delivered by David A. Angulo, M.D., President and CEO of SCYNEXIS.

Positive

• Presentation of preclinical efficacy data for SCY-247 at a major infectious disease conference
• Development of a second-generation antifungal candidate with potential for both IV and oral administration
• Potential for extensive tissue distribution and low drug-drug interaction of SCY-247

Negative

• None.

JERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations of preclinical efficacy and pharmacokinetic data on its second-generation fungerp candidate SCY-247 at IDWeek 2024 taking place in Los Angeles, CA from October 16-19, 2024.

Presentation details can be found below:

Oral Presentation:

Title:	Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections
Session:	Mycology Matters: Insights into Fungal Infections
Date/Time:	Thursday October 17, 2024 at 10:45 AM PDT
Location:	Los Angeles Convention Center, Room 403 B
Presenting author:	David A. Angulo, M.D., President and CEO of SCYNEXIS

Poster Presentation:

Title:	SCY-247: A Second-generation IV/Oral Triterpenoid Antifungal with Extensive Tissue Distribution and Pharmacokinetics, and Low Drug-Drug Interaction Potential
Session:	New Drug Development
Date/Time:	Friday October 18, 2024 at 12:15 – 1:30 PM PDT
Location:	Los Angeles Convention Center, Halls JK
Presenting author:	David A. Angulo, M.D., President and CEO of SCYNEXIS

For more information, see the IDWeek website here.

About SCY-247

SCY-247 is a second-generation antifungal compound, from a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids (fungerps), being developed to address the significant threat posed by antimicrobial resistance (AMR) in systemic fungal diseases with high mortality. The triterpenoid class of antifungals represents the first new class of antifungal compounds approved since 2001. These agents combine the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. SCY-247 is in pre-IND development stage and has demonstrated in vitro and in vivo broad-spectrum antifungal activity, including against multidrug resistant fungal pathogens. SCYNEXIS anticipates that the U.S. Food and Drug Administration (FDA) may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track designations for the IV and oral formulations of SCY-247.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps”. Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME^® (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. Additional antifungal assets from this novel class are currently in pre-clinical and discovery phase, including the compound SCY-247. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: SCYNEXIS anticipates that the U.S. Food and Drug Administration (FDA) may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track designations for the IV and oral formulations of SCY-247. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 28, 2024, and form 10-Q for the quarter ending June 30, 2024, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: 
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

FAQ

What is SCYNEXIS presenting at IDWeek 2024 regarding SCY-247?

SCYNEXIS is presenting preclinical efficacy and pharmacokinetic data on its second-generation fungerp candidate SCY-247 at IDWeek 2024. This includes an oral presentation on its efficacy in murine models of invasive fungal infections and a poster presentation on its tissue distribution, pharmacokinetics, and drug-drug interaction potential.

When and where will SCYNEXIS (SCYX) present the SCY-247 data at IDWeek 2024?

SCYNEXIS will present the SCY-247 data at IDWeek 2024 in Los Angeles, CA from October 16-19, 2024. The oral presentation is scheduled for October 17 at 10:45 AM PDT, and the poster presentation is on October 18 from 12:15 - 1:30 PM PDT.

What are the potential advantages of SCYNEXIS's (SCYX) SCY-247 antifungal candidate?

Based on the presentation titles, SCY-247 appears to be a second-generation triterpenoid antifungal with potential advantages including efficacy against invasive fungal infections, extensive tissue distribution, favorable pharmacokinetics, and low drug-drug interaction potential. It also has the potential for both IV and oral administration.